Table 2

Summary of the cellular immunotherapy

Case no.HLA class I A locusSource of autologous tumor cellTotal no. of injected cells (total no. of injections)Method of administrationCTL activityaAdverse effectbClinical ResponsecPeriod of remission (mo)
1 24 /31 Primary tumor2.1 × 109 (3)EndoscopicYesGrade 3 (hypotension)CR∼20
2 2 / Primary tumor5.3 × 109 (6)EndoscopicNoGrade 1 (fever)PD
3 24 /26 Primary tumor18 × 109 (9)EndoscopicYesGrade 1 (fever)PR11
4 2 /11 Pleural effusion1 × 109 (2)RegionalNoNonePD
5 2 / Metastatic lymph node5.8 × 109 (7)RegionalYesGrade 1 (fever)PR9
6 26 /33 Pleural effusion3.9 ± 109 (5)RegionalYesNonePD
7 NTd Pleural effusion1.2 × 109 (2)RegionalNoNonePD
8 24 /31 Primary tumor4.9 × 109 (6)EndoscopicNoGrade 1 (fever)SR8
9 24 /11 Metastatic lymph node7 × 109 (8)RegionalYesGrade 1 (fever)PR7
10 31 /11 Pleural effusion2 × 109 (3)RegionalNoGrade 1 (fever)PD
11 24 / Ascites3.6 × 109 (6)RegionalNoGrade 2 (nausea, diarrhea)SR∼13
  • a The term CTL activity was used in this study if the activated PBMCs produced the significantly higher levels of IFN-γ or percentage of cytotoxicity (P < at least 0.05 by a two-tailed Student’s t test) by recognition of the autologous tumor cells when compared with those in the allogenic tumor cell lines.

  • b Common toxicity criteria of the National Cancer Institute.

  • c CR, (disappearance of all measurable mass); PR, (>50% reduction in the size of the mass); SR, (<50% reduction in the size of the mass); PD, (increase in the size of the mass).

  • d Not tested.